BIO Finance Trends: Drug Developers Face Harsh Realities As Funding Constraints Continue

Dealmaking Has Become A Cash Alternative

 
• By Mandy Jackson
  
Declining biotech valuations are not expected to reverse course soon (Shutterstock)

More from BIO

More from Conferences